US › Healthcare

Filana Therapeutics, Inc. (FLNA)

US · Healthcare · Biotechnology

$0.72+5.88%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.6M

EPS

$-0.18

EPS estimate

$-0.22

EPS came in at -0.18 against a street estimate of -0.22 — a beat of 18.2%.

Key statistics

Market cap

$37.3M

Forward P/E

151.5

P/B

0.59

Book value

$1.32

EPS (TTM)

$-0.87

52-week high

$4.98

52-week low

$0.71

50-day MA

$0.97

200-day MA

$1.68

Beta

-0.70

Analyst view

with an average price target of $6.50.

Shareholding

Insiders

2.05%

Institutions

26.72%

Largest institutional holders

Fund	Stake
Marshall Wace Asset Management Ltd	4.17%
Vanguard Capital Management, LLC	4.00%
Two Sigma Investments LLC	3.54%
BlackRock Inc	2.93%
Geode Capital Management, LLC	1.23%
D. E. Shaw & Co LP	1.00%
GMT Capital Corp	0.93%
Susquehanna International Group, LLP	0.93%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Filana Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.